Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 13:22:454-467.
doi: 10.1016/j.omto.2021.06.016. eCollection 2021 Sep 24.

Systematic review of the immunological landscape of Wilms tumors

Affiliations
Review

Systematic review of the immunological landscape of Wilms tumors

Francesca Palmisani et al. Mol Ther Oncolytics. .

Abstract

Results of immunotherapy in childhood solid cancer have been so far, with the exception of neuroblastoma, quite disappointing. Lack of knowledge of the immune contexture of these tumors may have contributed to the failure of immunotherapies so far. Here, we systematically reviewed the literature regarding the immunology of Wilms tumor (WT), one of the most frequent pediatric solid tumors of the abdomen. In Wilms tumor patients the high cure rate of >90%, achieved by the combination of surgery and radio-chemotherapy, is at the expense of a high early and late toxicity. Moreover, treatment-resistant entities, such as diffuse anaplastic tumors or recurrent disease, still pose unsolved clinical problems. Successful immunotherapy could represent a novel and possibly less-toxic treatment option. Employing the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) method of literature search, we analyzed the current knowledge of the immunological landscape of Wilms tumors in terms of tumor microenvironment, prognostic implications of single biomarkers, and immunotherapy response.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests. M.B. receives research funds and consultant fees from Boehringer Ingelheim and Bristol Myers Squibb.

Figures

None
Graphical abstract
Figure 1
Figure 1
PRISMA flow diagram Schematic view of the search strategy according to PRISMA flow diagram. WT, Wilms tumor.
Figure 2
Figure 2
Similarities between Wilms tumor and placenta microenvironment On the left, schematic view of the immune microenvironment of Wilms tumor and its main actors. On the right, schematic view of the immune microenvironment of the placenta with some of its main actors. On the far right, figure legend.

References

    1. Pagès F., Mlecnik B., Marliot F., Bindea G., Ou F.-S., Bifulco C., Lugli A., Zlobec I., Rau T.T., Berger M.D. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–2139. - PubMed
    1. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 2019;38:255. - PMC - PubMed
    1. Wright K.D., Green D.M., Daw N.C. Late effects of treatment for wilms tumor. Pediatr. Hematol. Oncol. 2009;26:407–413. - PMC - PubMed
    1. Bhakta N., Liu Q., Ness K.K., Baassiri M., Eissa H., Yeo F., Chemaitilly W., Ehrhardt M.J., Bass J., Bishop M.W. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE) Lancet. 2017;390:2569–2582. - PMC - PubMed
    1. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., Gadgeel S.M., Hida T., Kowalski D.M., Dols M.C., OAK Study Group Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265. - PMC - PubMed

LinkOut - more resources